Leonie Heron

Leonie Heron

Auto-generated profile, based on publicly available information

Leonie Heron

Institute of Social and Preventive Medicine, University of Bern

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
Mark TullyMark Tully
Mark Tully
CMCairmeal McBride
Cairmeal McBride
LHLeonnie Heron
Leonnie Heron
RHRuth Hunter
Ruth Hunter
The new generation of activity monitors allow users to upload their data to the internet and review progress. The aim of this study is to validate the Fitbit Zip as a measure of free-living physical activity.

26 May 2022 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
DBDiana Buitrago-Garcia
Diana Buitrago-Garcia
AIAziz Mert Ipekci
Aziz Mert Ipekci
LHLeonie Heron
Leonie Heron
HIHira Imeri
Hira Imeri
LALucia Araujo-Chaveron
Lucia Araujo-Chaveron
NLNicola Low
Nicola Low
Background: Debate about the level of asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection continues. The amount of evidence is increasing and study designs have changed over time. We updated a living systematic review to address 3 questions: (1) Among people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a population is accounted for by people who are asymptomatic or presymptomatic?Methods and findings: The protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched PubMed, Embase, bioRxiv, and medRxiv, aggregated in a database of SARS-CoV-2 literature, most recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented symptom status at the beginning and end of follow-up, or mathematical modelling studies were included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses were done using random effects models. Review question (1): We included 130 studies. Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall (interquartile range (IQR) 14% to 50%, prediction interval 2% to 90%), or in 84 studies based on screening of defined populations (IQR 20% to 65%, prediction interval 4% to 94%). In 46 studies based on contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% confidence interval (CI) 15% to 25%, prediction interval 2% to 70%). (2) The secondary attack rate in contacts of people with asymptomatic infection compared with symptomatic infection was 0.32 (95% CI 0.16 to 0.64, prediction interval 0.11 to 0.95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2 transmission from presymptomatic individuals was higher than from asymptomatic individuals. Limitations of the evidence include high heterogeneity and high risks of selection and information bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated.Conclusions: Based on studies published up to July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. Summary estimates from meta-analysis may be misleading when variability between studies is extreme and prediction intervals should be presented. Future studies should determine the asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2.Review protocol: Open Science Framework (https://osf.io/9ewys/)

25 March 2019 in Journal of Epidemiology and Community Health
Verified
Journal Article
Open access
PDF file
LHLeonie Heron
Leonie Heron
COCiaran O'Neill
Ciaran O'Neill
Helen McAneneyHelen McAneney
Helen McAneney
FKFrank Kee
Frank Kee
Mark TullyMark Tully
Mark Tully
Background Growing evidence indicates that prolonged sedentary behaviour increases the risk of several chronic health conditions and all-cause mortality. Sedentary behaviour is prevalent among adults in the UK. Quantifying the costs associated with sedentary behaviour is an important step in the development of public health policy. Methods National Health Service (NHS) costs associated with prolonged sedentary behaviour (≥6 hours/day) were estimated over a 1-year period in 2016–2017 costs. We calculated a population attributable fraction (PAF) for five health outcomes (type 2 diabetes, cardiovascular disease [CVD], colon cancer, endometrial cancer and lung cancer). Adjustments were made for potential double-counting due to comorbidities. We also calculated the avoidable deaths due to prolonged sedentary behaviour using the PAF for all-cause mortality. Results The total NHS costs attributable to prolonged sedentary behaviour in the UK in 2016–2017 were £0.8 billion, which included expenditure on CVD (£424 million), type 2 diabetes (£281 million), colon cancer (£30 million), lung cancer (£19 million) and endometrial cancer (£7 million). After adjustment for potential double-counting, the estimated total was £0.7 billion. If prolonged sedentary behaviour was eliminated, 69 276 UK deaths might have been avoided in 2016. Conclusions In this conservative estimate of direct healthcare costs, prolonged sedentary behaviour causes a considerable burden to the NHS in the UK. This estimate may be used by decision makers when prioritising healthcare resources and investing in preventative public health programmes.

4 June 2020 in Cities & Health
Verified
Journal Article
Open access
RHRuth Hunter
Ruth Hunter
MDMary A.T. Dallat
Mary A.T. Dallat
Mark TullyMark Tully
Mark Tully
LHLeonie Heron
Leonie Heron
COCiaran O’nEill
Ciaran O’nEill
FKFrank Kee
Frank Kee
Evidence supports the multi-functional nature of urban green space, and so economic evaluations should have a broad lens in order to capture their full impact. Given the evidence for a range of health, wellbeing, social and environmental benefits of such interventions, we modelled the potential social return on investment of a new urban greenway intervention in Belfast, Northern Ireland. Areas that the greenway was purported to impact upon included: land and property values; flood alleviation; tourism; labour employment and productivity; quality of place; climate change; and, health. The most recent and applicable evidence pre-development of the greenway for each area was summarised to obtain an ‘effect estimate’; this was then applied to available data for the greenway area and the impact estimated and monetised using various methods. To calculate the Benefit Cost Ratio all seven monetary benefits were summed, for both a worst case and best case scenario, and divided by the total investment cost. The Benefit Cost Ratio ranged from 2.88 to 5.81 (i.e. for every £1.00 invested in the greenway, there would be £2.00–6.00 returned). This is one of the first studies to conduct a social return on investment of a new urban greenway estimating the potential benefits.

1 January 2023 in Journal of Physical Activity and Health
Verified
Journal Article
Closed access
PDF file
JMJoseph Murphy
Joseph Murphy
Karen MiltonKaren Milton
Karen Milton
Matthew MclaughlinMatthew Mclaughlin
Matthew Mclaughlin
TSTrevor Shilton
Trevor Shilton
GMGabriella McLoughlin
Gabriella McLoughlin
RSRachel Sutherland
Rachel Sutherland
Background: There is limited understanding of the challenges experienced and supports required to aid effective advocacy of the Global Action Plan on Physical Activity (GAPPA). The purpose of this study was to assess the challenges experienced and supports needed to advocate for the GAPPA across countries of different income levels. Methods: Stakeholders working in an area related to the promotion of physical activity were invited to complete an online survey. The survey assessed current awareness and engagement with the GAPPA, factors related to advocacy, and the perceived challenges and supports related to advocacy for implementation of the GAPPA. Closed questions were analyzed in SPSS, with a Pearson’s chi-square test used to assess differences between country income level. Open questions were analyzed using inductive thematic analysis. Results: Participants (n = 518) from 81 countries completed the survey. Significant differences were observed between country income level for awareness of the GAPPA and perceived country engagement with the GAPPA. Challenges related to advocacy included a lack of support and engagement, resources, priority, awareness, advocacy education and training, accessibility, and local application. Supports needed for future advocacy included guidance and support, cooperation and alliance, advocacy education and training, and advocacy resources. Conclusions: Although stakeholders from different country income levels experience similar advocacy challenges and required supports, how countries experience these can be distinct. This research has highlighted some specific ways in which those involved in the promotion of physical activity can be supported to scale up advocacy for the GAPPA. When implementing such supports, consideration of regional, geographic, and cultural barriers and opportunities is important to ensure they are effective and equitable.

30 January 2022 in medRxiv
Verified
Preprint
Open access
PDF file
DBDiana Buitrago-Garcia
Diana Buitrago-Garcia
AIAziz Mert Ipekci
Aziz Mert Ipekci
LHLeonie Heron
Leonie Heron
HIHira Imeri
Hira Imeri
LALucia Araujo-Chaveron
Lucia Araujo-Chaveron
NLNicola Low
Nicola Low
BACKGROUND: Debate about the level of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues. The amount of evidence is increasing and study designs have changed over time. We updated a living systematic review to address three questions: (1) Amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) What is the infectiousness of asymptomatic and presymptomatic, compared with symptomatic, SARS-CoV-2 infection? (3) What proportion of SARS-CoV-2 transmission in a population is accounted for by people who are asymptomatic or presymptomatic? METHODS AND FINDINGS: The protocol was first published on 1 April 2020 and last updated on 18 June 2021. We searched PubMed, Embase, bioRxiv and medRxiv, aggregated in a database of SARS-CoV-2 literature, most recently on 6 July 2021. Studies of people with PCR-diagnosed SARS-CoV-2, which documented symptom status at the beginning and end of follow-up, or mathematical modelling studies were included. Studies restricted to people already diagnosed, of single individuals or families, or without sufficient follow-up were excluded. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with a bespoke checklist and modelling studies with a published checklist. All data syntheses were done using random effects models. Review question (1): We included 130 studies. Heterogeneity was high so we did not estimate a mean proportion of asymptomatic infections overall (interquartile range 14-50%, prediction interval 2-90%), or in 84 studies based on screening of defined populations (interquartile range 20-65%, prediction interval 4-94%). In 46 studies based on contact or outbreak investigations, the summary proportion asymptomatic was 19% (95% CI 15-25%, prediction interval 2-70%). (2) The secondary attack rate in contacts of people with asymptomatic infection compared with symptomatic infection was 0.32 (95% CI 0.16-0.64, prediction interval 0.11-0-95, 8 studies). (3) In 13 modelling studies fit to data, the proportion of all SARS-CoV-2 transmission from presymptomatic individuals was higher than from asymptomatic individuals. Limitations of the evidence include high heterogeneity and high risks of selection and information bias in studies that were not designed to measure persistently asymptomatic infection, and limited information about variants of concern or in people who have been vaccinated. CONCLUSIONS: Based on studies published up to July 2021, most SARS-CoV-2 infections were not persistently asymptomatic and asymptomatic infections were less infectious than symptomatic infections. Summary estimates from meta-analysis may be misleading when variability between studies is extreme and prediction intervals should be presented. Future studies should determine the asymptomatic proportion of SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection. Without prospective longitudinal studies with methods that minimise selection and measurement biases, further updates with the study types included in this living systematic review are unlikely to be able to provide a reliable summary estimate of the proportion of asymptomatic infections caused by SARS-CoV-2. REVIEW PROTOCOL: Open Science Framework ( https://osf.io/9ewys/ ) AUTHOR SUMMARY: Why was this study done?: ▪ The proportion of people who will remain asymptomatic throughout the course of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (covid-19), is debated. ▪ Studies that assess people at just one time point overestimate the proportion of true asymptomatic infection because those who go on to develop covid-19 symptoms will be wrongly classified as asymptomatic, but other types of study might underestimate the proportion if, for example, people with symptoms are more likely to be included in a study population. ▪ The number of published studies about SARS-CoV-2 is increasing continuously, types of studies are changing and, since 2021, vaccines have become available, and variants of concern have emerged. What did the researchers do and find?: ▪ We updated a living systematic review through 6 July 2021, using automated workflows that speed up the review processes, and allow the review to be updated when relevant new evidence becomes available. ▪ In 130 studies, we found an interquartile range of 14-50% (prediction interval 2-90%) of people with SARS-CoV-2 infection that was persistently asymptomatic; owing to heterogeneity, we did not estimate a summary proportion. ▪ Contacts of people with asymptomatic SARS-CoV-2 infection are less likely to become infected than contacts of people with symptomatic infection (risk ratio 0.38, 95% CI 0.16-0.64, prediction interval 0.11-0.95, 8 studies). What do these findings mean?: ▪ Up to mid-2021, most people with SARS-CoV-2 were not persistently asymptomatic and asymptomatic infection was less infectious than symptomatic infection. ▪ In the presence of high between-study variability, summary estimates from meta-analysis may be misleading and prediction intervals should be presented. ▪ Future studies about asymptomatic SARS-CoV-2 infections caused by variants of concern and in people with immunity following vaccination or previous infection should be specifically designed, using methods to minimise biases in the selection of study participants and in ascertainment, classification and follow-up of symptom status.